Invitation only · Singapore
APAC MedTech innovation, verified and piloted.
Amplifai for Innovators is the invitation-only workspace where five roles — startups, HCPs, investors, advisors and professional communities — share verified profiles, products and use cases. Private by default, discoverable only where each side chooses.
NZmark — APACMed's official partner and exclusive operator of the MedTech Forum's Day-1 Innovation Stage & Startup Zone (MTF27–29).
Who Innovator is for
Five categories, one dataset.
The same verified figures mean different things depending on where you sit. Each category sees the number that matters most to its work.
Startups & scaleups
Claim your verified profile, publish products and clinical use cases, and track engagement — no cold pitches, no directory browsing.
HCPs
Publish a verified site profile. Send Innovation Inquiries to startups. Choose exactly who sees what, per audience.
Investors
See the acquisition and strategic-exit environment across a named, verified buyer set — not survey estimates.
Advisors
Access the visibility gaps that shape advisory mandates: revenue exposure, challenge mapping and verified claims.
Professional communities
Give your members structured, evidenced access to the dataset they cannot assemble themselves.
Figures as at August 2026
What you can publish
Structured surfaces, private-by-default fields.
Products & services
Regulatory class, TRL, reimbursement status, and per-market posture — with source provenance on every field.
Clinical use cases
Site context, patient impact, endpoints, and paired documents — visibility controlled per audience.
Innovation Inquiries
Structured HCP-to-startup requests with an evidence-first response format and a defined response window, confirmed when an inquiry is opened.
The Day-1 pathway
From verified profile to MedTech Forum Stage.
Publishing here is the first checkpoint. Amplifai analysts advance the strongest teams through pathway phases and onto the Day-1 Innovation Stage & Startup Zone at the APACMed MedTech Forum. The MTF27 line-up (dates to be confirmed, Suntec Singapore) — stage selection for MTF27 is not yet open.
How the pathway runs
- 01.Claim & verify — profile private until Amplifai confirms.
- 02.Publish — products, use cases, per-audience visibility.
- 03.Engage — respond to Innovation Inquiries from HCPs.
- 04.Progress — analyst-led selection for the Day-1 stage.
The problems are in the filings
Fifteen challenges. Sixty-two filings. Zero guesswork.
Every challenge in the Amplifai framework was tested against what the world's top-traded MedTech companies disclose in their regulatory filings — not against what an industry survey says.
| Challenge | Named as a risk in |
|---|---|
| Supply Chain De-risking | 98% |
| Reimbursement & Coverage Compression | 78% |
| Severe VBP Margin Compression | 76% |
| Opaque Distributor Networks | 74% |
| Portfolio Separation & Regulatory Transfer | 60% |
| Equipment Maintenance Downtime | 19% |
Find out which of them are buying, and what they have written down.
Source: Amplifai analysis of 62 annual regulatory filings, read in full, August 2026. Method available on request.
Figures as at August 2026
How verification works
Every claim we publish is date-stamped.
Amplifai independently verifies each organisation before its profile is visible to others. Regulatory status, reimbursement status and TRL evidence are held admin-side and re-checked at defined cadences.
01
Analyst review
Registry, corporate filings and documented product evidence assessed off-platform.
02
Verified badge
Only cleared organisations render the dated Verified badge. Flagged records stay off public surfaces.
03
Re-verification
Status is refreshed at each program milestone. Owners are notified before badges expire.
The market on the ground
Singapore
A concentrated, English-contracting, well-regulated system — and the entry point most international MedTech companies use for the region.
- 31%
- Growth in national healthcare development expenditure this year
- Source: Singapore Budget 2026
- S$23bn
- National health budget, FY2026
- Source: Singapore Budget 2026, Head O — Ministry of Health
- 12,767
- Acute hospital beds, across 20 hospitals
- Source: Singapore MOH, 2025
- 620,000
- Acute hospital admissions in a year
- Source: Singapore MOH, 2023
- S$18bn flows into public hospitals and healthcare institutions in FY2026.Source: Singapore Budget 2026, Head O — Ministry of Health
- Roughly three-quarters of Singapore's medical device demand runs through the public health system, across three hospital clusters.Source: US ITA Country Commercial Guide
- Public hospitals hold 80% of all hospital beds.Source: Singapore MOH
- Health spending is about 4% of GDP.Source: World Bank, 2023
- The domestic medical device market is between US$2bn and US$4bn, growing at about 8% a year.Source: industry research
- This year's healthcare capital budget funds Alexandra Hospital, the new Eastern General Hospital, and the Next Generation Electronic Medical Record programme.Source: Singapore Budget 2026
Singapore is not a volume market. It is a reference market and a regional headquarters — a place to prove a product inside a system that publishes its capital budget and concentrates its buying.
Figures as at August 2026
The region behind the demand
Asia-Pacific
The region these companies are being judged on — and where the demand curve is steepest.
- 503m
- People aged 65 and over in Asia-Pacific today
- Source: UN ESCAP, 2024
- 1 billion
- Projected by 2050, close to one person in five
- Source: UN ESCAP
- US$2 trillion
- Annual health expenditure across East Asia and the Pacific
- Source: World Bank, 2023
- 7%
- Health spending as a share of GDP, regional average
- Source: World Bank, 2023
- The Asia-Pacific medical device market is estimated at between US$78bn and US$143bn — research houses differ by nearly double on the same year.Source: industry research
- There are about 5 hospital beds per 1,000 people across the region.Source: World Bank, 2023
- And about 2 doctors and 4 nurses per 1,000 people.Source: World Bank, 2022
- Median age across the region is rising from 33 today toward 41 by 2050.Source: UN ESCAP
Ageing is the demand driver underneath all fifteen challenges. It is the one variable in this region that is not forecast, but already counted.
Figures as at August 2026
NZmark — APACMed's official partner and exclusive operator of the MedTech Forum's Day-1 Innovation Stage & Startup Zone (MTF27–29).